Table 1. List of up-regulated genes after ovalbumin (OVA) challenge

Supplemental Table1c: Differentially expressed genes between high in SIL/TAL patients

Supplemental Table1b: Differentially expressed genes between high in HOXA patients

Supplemental Table1a: Differentially expressed genes between Myeloid-like patients

Table S4. Fifty most up-regulated genes in HBV-associated acute liver failure (ALF)  31 of which were part of an overriding B cell gene signature with a total of 77 B cell–related transcripts

Table S1. NSCLC tumor signature (the longest)

Table S6. NSCLC patient survival signature

Table S2. A final list of 187 probe sets that were differentially expressed in all NSCLC samples  determined as the Tumor Signature (LONG)

Table S3. A subset of the list of probe sets in the Tumor Signature  5 out of 187  able to distinguish non-cancerous tissues from malignant NSCLC with an accuracy of 98%  using Prediction Analysis of Microarrays; the Tumor Signature (SHORT)

Table S4. NSCLC histology signature (long)

Table S5. NSCLC histology signature (short)

Supplemental Table S6.  Genes differentially expressed in ovarian surface epithelium and ovarian cancer compared to ovarian cystic epithleium.  \FC(S)\" refers to the fold-change in ovarian surface "

Supplemental Table S5.  Genes differentially expressed in ovarian cystic epithelium and ovarian cancer compared to ovarian surface epithelium.  \FC(C)\" refers to the fold-change in ovarian cyst compared to ovarian surface epithelium       "

Supplemental Table S4.  Genes differentially expressed in ovarian cystic epithelium compared to ovarian surface epithelium. \FC(C)\" refers to the fold-change in ovarian cystic epithelium compared to "

Table 2. Down-regulated microRNAs differentially expressed (P < 0.05) between SzS (n = 21) and CD4+ controls (n = 6) showing chromosomal location  inclusion in microRNA clusters and number of predicted target genes up-regulated in Sz.18 MicroRNAs also associated (P < 0.05) with B-cell lymphoma8 are indicated in bold.